INBRX-106 advanced solid tumor study

Study overview

This open-label, multicenter, first-in-human Phase 1/2 study is evaluating INBRX-106 by itself and in combination with pembrolizumab in people with locally advanced or metastatic solid tumors. A listed open cohort includes non-small cell lung cancer. The study uses dose-escalation and multicohort stages to examine the investigational treatment in carefully defined participant groups.

What the research examines

Early-phase research commonly evaluates safety, tolerability, dose selection, and how an investigational medicine behaves in the body. Expansion groups may also assess preliminary antitumor activity. Procedures can include examinations, laboratory tests, imaging, tumor measurements, and monitoring for side effects. Participants assigned to a combination group may receive pembrolizumab according to the protocol. INBRX-106 is investigational, so its benefits and risks are not fully established. Pembrolizumab also has specific risks reviewed during informed consent.

Asking about participation

Eligibility may depend on tumor type, disease status, previous treatments, general health, laboratory findings, and other protocol requirements. Cohort availability can change as groups open, pause, fill, or close. Screening does not guarantee enrollment, and contacting California Research Institute does not obligate you to participate.

Participation is voluntary. The research team explains required visits, procedures, foreseeable risks, alternatives, privacy protections, and participant rights. You may review the study with your physician, family, or another trusted adviser before deciding.

For current information, call (323) 660-6200 or email trials@caresinst.org. Please do not email medical records, insurance details, or sensitive health information. This page is educational and does not replace medical advice.

The coordinator can explain the current cohort and screening process.

View all clinical trials